Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy
Italy faces challenges with late HIV diagnoses, which leads to worse health outcomes and higher healthcare costs. In Italy, the proportion of late diagnoses (i.e., a CD4 count <350 cells/mm3) has increased to 60% in 2020—10% higher than the European average (1). With an estimated 13,000–15,000 undiagnosed HIV cases in Italy, innovative testing strategies are urgently needed Read More >
When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal
In 2019, the previous UK government set the ambitious target of eliminating HIV transmission within the UK by 2030. While great progress has been made in HIV prevention and treatment in the UK, with England reaching the UNAIDS 95-95-95 target in 20231, past evidence suggested that the goal of ‘elimination’ by 2030 is unlikely to Read More >
The use of monoclonal antibodies (mAbs) as COVID-19 pre-exposure prophylaxis (PrEP) for immunocompromised patients with haematological malignancies in Germany
Patients with haematological malignancies (HM) are particularly vulnerable to severe outcomes from COVID-19, with mortality rates reaching up to 34% in this patient group following COVID-19 infection (1). Although COVID-19 vaccines have been widely effective in reducing severe outcomes in the general population, patients with haematological malignancies often have limited immune responses to vaccination, even Read More >